Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 82

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 82
---
 and distribution
capabilities would adversely impact the commercialization of these products. If we choose to collaborate with third parties that have
direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of
our own sales force and distribution systems, we may not be able to enter into collaborations or hire consultants or external service
providers to assist us in pharmaceutical product sales, marketing and distribution functions on acceptable financial terms, or at all.
In addition, our pharmaceutical product revenues and our profitability, if any, may be lower if we rely on third parties for these functions
than if we were to market, sell and distribute any pharmaceutical products that we develop ourselves. We likely will have little control
over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our pharmaceutical
products effectively. If we are not successful in commercializing our pharmaceutical products, either on our own or through arrangements
with one or more third parties, we may not be able to generate any future pharmaceutical product revenue and we would incur significant
additional losses.

Our investment strategy and future growth relies on a number
of assumptions, some or all which may not be realized.

Our strategy for investment and plans for future expansion are founded
upon a range of assumptions. These assumptions, particularly for our pharmaceutical product candidates, include considerations related
to the adoption of a specific therapy, the price at which the product candidate might be sold (or reimbursed by third party payors), the
occurrence of a particular medical condition, the preference for our product candidate over competing therapies, and the size of patient
populations. Some or all of these assumptions might prove to be inaccurate because our ability to predict whether our product candidates
will attain significant market acceptance or if a market for our product candidates will indeed materialize as anticipated, is inherently
uncertain. If any of these assumptions turn out to be incorrect or overly optimistic, it could have a substantial and adverse impact on
our results and future prospects.

Our future success depends on our ability to retain key employees,
directors, consultants and advisors and to attract, retain and motivate qualified personnel.

We heavily depend on the expertise of our executive officers, directors,
and scientific teams for their expertise in areas such as management, research and development, drug development, finance, and business
development, both for the Company and our subsidiaries and investments. Their departure could adversely impact our research, development,
and our licensing pursuits, and impede the execution of our business strategy